BioSpace News Archive

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic and fibrotic pathways, reported financial results for the full year ended December 31, 2023, and provided corporate updates.

MiLaboratories, a leader in developing best-in-class software for immunological data analysis, proudly announces the official launch of Platforma.bio . This groundbreaking computational biology platform, powered by AI large language models, is designed to significantly streamline, and simplify biological analysis, making it more accessible to researchers across various disciplines.

ONO Pharmaceuticals, Co., Ltd. announced it has completed target patient enrollment of the first arm of the PROSPECT Study, a Phase 2 clinical trial evaluating the safety and efficacy of tirabrutinib in U.S. patients with relapsed or refractory primary central nervous system lymphoma.

Verge Genomics and Ferrer have announced a strategic collaboration to co-develop VRG50635, Verge’s lead drug candidate, for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis, in Europe, Central and South America, Southeast Asia, and Japan.

Nkarta, Inc. announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and pre-funded warrants to purchase 3,000,031 shares of common stock.

Apogee Therapeutics, Inc. today announced that it has initiated dosing of healthy volunteers in its first clinical trial for APG808, a novel subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-4Rα, which is being developed as a treatment for people living with moderate-to-severe COPD, asthma and other I&I diseases.

Axsome Therapeutics, Inc. announced that AXS-12, a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, achieved the primary endpoint and significantly reduced the frequency of cataplexy attacks as compared to placebo in patients with narcolepsy in the SYMPHONY Phase 3 trial.

Sagimet Biosciences Inc. today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced that it is part of a diverse research team of international experts selected as awardees in this year’s Cancer Grand Challenges competition.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received a Top Workplaces USA award for the third consecutive year.